Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISMS pharmacogenetic long-term follow-up study
NL-OMON34946Phase 4Active, not recruiting
- Sponsor
- Merck Serono
- Start
- May 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Merck Serono. Primary endpoints: Association between SNP markers and treatment response, Genetic markers and 1 more. Started May 2010; status: active, not recruiting.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON34946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34946.